Cheng Ye, Chen Yanna, Wang Guodong, Liu Pei, Xie Guiling, Jing Huan, Chen Hongtao, Fan Youlin, Wang Min, Zhou Jun
Department of Anesthesiology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Department of Anesthesiology, The Eighth People's Hospital of Guangzhou, Guangzhou, China.
Front Med (Lausanne). 2022 May 12;9:736006. doi: 10.3389/fmed.2022.736006. eCollection 2022.
Chronic kidney disease (CKD) is defined by persistent urine aberrations, structural abnormalities, or impaired excretory renal function. Diabetes is the leading cause of CKD. Their common pathological manifestation is renal fibrosis. Approximately half of all patients with type 2 diabetes and one-third with type 1 diabetes will develop CKD. However, renal fibrosis mechanisms are still poorly understood, especially post-transcriptional and epigenetic regulation. And an unmet need remains for innovative treatment strategies for preventing, arresting, treating, and reversing diabetic kidney disease (DKD). People believe that protein methylation, including histone and non-histone, is an essential type of post-translational modification (PTM). However, prevalent reviews mainly focus on the causes such as DNA methylation. This review will take insights into the protein part. Furthermore, by emphasizing the close relationship between protein methylation and DKD, we will summarize the clinical research status and foresee the application prospect of protein methyltransferase (PMT) inhibitors in DKD treatment. In a nutshell, our review will contribute to a more profound understanding of DKD's molecular mechanism and inspire people to dig into this field.
慢性肾脏病（CKD）的定义为持续性尿液异常、结构异常或肾脏排泄功能受损。糖尿病是CKD的主要病因。它们共同的病理表现是肾纤维化。大约一半的2型糖尿病患者和三分之一的1型糖尿病患者会发展为CKD。然而，肾纤维化机制仍未被充分了解，尤其是转录后和表观遗传调控方面。对于预防、阻止、治疗和逆转糖尿病肾病（DKD）的创新治疗策略仍存在未满足的需求。人们认为蛋白质甲基化，包括组蛋白和非组蛋白甲基化，是一种重要的翻译后修饰（PTM）类型。然而，目前流行的综述主要关注DNA甲基化等原因。本综述将深入探讨蛋白质部分。此外，通过强调蛋白质甲基化与DKD之间的密切关系，我们将总结临床研究现状并展望蛋白质甲基转移酶（PMT）抑制剂在DKD治疗中的应用前景。简而言之，我们的综述将有助于更深入地理解DKD的分子机制，并激励人们深入研究该领域。
